Skiplink Navigation

Main Features

Roche launches search for new schizophrenia treatment

Roche CEO, Franz B Humer, presenting the company's half-yearly results last year

(Keystone Archive)

The pharmaceuticals group, Roche, and the Icelandic biotechnology company, Decode Genetics, say they are to begin a drug discovery programme to find new treatments and diagnostic tests for schizophrenia.

The two companies are also to collaborate to create new drugs for the treatment of a disease which causes the narrowing of the arteries.

Decode has identified genes linked to both illnesses. Roche pays Decode for its gene discoveries and has the rights to develop the company's findings into diagnostic products and medicines.

Decode has bought exclusive access to Iceland's health records and is gathering genetic information from the country's population.

swissinfo with agencies


Neuer Inhalt

Horizontal Line

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.

Click here to see more newsletters